ZVRA supply chain intelligence for Zevra Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Zevra Therapeutics, Inc. (ZVRA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| LADX | LadRx Corporation | 90% | Reciprocal relationship from LADX graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from LADX graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare… |
| LADX | LadRx Corporation | 90% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| RELIEF | RELIEF | 90% | Pursuant to the Relief License Agreement, Zevra is obligated to pay royalties of 10% of U.S. net sales up to a maximum of $45.0 million, plus specified regulatory milestones, for total payments to Re… |
| XOMA-CORPORATION | XOMA-CORPORATION | 90% | Under the XOMA License Agreement, XOMA is entitled to a mid-single digit percentage royalty with respect to net sales of MIPLYFFA as well as milestone payments based on future potential sales and reg… |
| AQST | Aquestive Therapeutics, Inc. | 85% | Under our March 2012 termination agreement with Aquestive Therapeutics, Aquestive has the right to receive a royalty amount equal to 10% of any value generated by AZSTARYS and any product candidates … |
| AQST | Aquestive Therapeutics, Inc. | 85% | Reciprocal relationship from AQST graph: Reciprocal relationship from ZVRA graph: Under our March 2012 termination agreement with Aquestive Therapeutics, Aquestive has the right to receive a royalty … |
| RELIEF-THERAPEUTICS-SA | RELIEF-THERAPEUTICS-SA | 80% | On August 30, 2023, Acer and Relief Therapeutics SA (“Relief”) entered into an exclusive license agreement |
| AYTU | Aytu BioPharma, Inc. | 72% | Reciprocal relationship from AYTU graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potent… |
| AYTU | Aytu BioPharma, Inc. | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from ZVRA graph: vernment contracts or future orders under existing contracts and civil and criminal liability, including False Claims… |
| MYGN | Myriad Genetics, Inc. | 72% | vernment contracts or future orders under existing contracts and civil and criminal liability, including False Claims Act liability, exclusion from participation in federal health care programs, and … |
| NVSEF | Novartis AG | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, poten… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ZVRA graph: . I n addition, we have solicited and applied for trademarks for the Zevra logo and several potential trade names an… |
| ORANY | ORANY | 72% | . I n addition, we have solicited and applied for trademarks for the Zevra logo and several potential trade names and logos for future product candidates. Third parties may oppose or attempt to cance… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from SUPN g… |
| XOMA | XOMA Royalty Corporation | 72% | Reciprocal relationship from XOMA graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from XOMA graph: Item 4. Mine Safety Disclosures 70 Item 5. Other Information… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| COMMAVE-THERAPEUTICS-SA | COMMAVE-THERAPEUTICS-SA | 92% | Commave has agreed to pay the Company a total of $50.0 million in cash, and the Company has agreed to sell, transfer, and assign to Commave all of the Company's right, title, and interest in and to c… |
| COMMAVE | COMMAVE | 90% | We entered into the AZSTARYS License Agreement with Commave pursuant to which we granted an exclusive, worldwide license to Commave to develop, manufacture and commercialize AZSTARYS |
| AYTU | Aytu BioPharma, Inc. | 72% | Reciprocal relationship from AYTU graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from AYTU graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from AYTU g… |
| AYTU | Aytu BioPharma, Inc. | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| LADX | LadRx Corporation | 72% | Reciprocal relationship from LADX graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potent… |
| LADX | LadRx Corporation | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| MYGN | Myriad Genetics, Inc. | 72% | that Corium will dedicate to the development, manufacturing or commercialization of AZSTARYS. Our ability to generate revenue under the AZSTARYS License Agreement will depend, in part, on Corium’s ab… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from MYGN g… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from NVSE… |
| NVSEF | Novartis AG | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| ORANY | ORANY | 72% | . I n addition, we have solicited and applied for trademarks for the Zevra logo and several potential trade names and logos for future product candidates. Third parties may oppose or attempt to cance… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from ORAN… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potent… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neurocognitive impairments, if ammonia levels … |
| ACER-THERAPEUTICS-INC | ACER-THERAPEUTICS-INC | 62% | activities of a VIE. To assess whether the Company has the obligation to absorb losses of the VIE or the rights to receive benefits from the VIE that could potentially be significant to the VIE, the … |
| CITIZENS-JMP-SECURITIES-LLC | CITIZENS-JMP-SECURITIES-LLC | 62% | n weight. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management… |
| PERCEPTIVE-CREDIT-HOLDINGS | PERCEPTIVE-CREDIT-HOLDINGS | 62% | n weight. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management… |
| SHANGHAI-ARK-BIOPHARMACEUTICAL-LTD | SHANGHAI-ARK-BIOPHARMACEUTICAL-LTD | 62% | ased on weight. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic mana… |
| US-LLC | US-LLC | 62% | n weight. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management… |
| XOMA-CORPORATION | XOMA-CORPORATION | 62% | n weight. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ZVRA-DEBT | Debt stack $1.1M | 90% | Market cache reports total debt of $1.1M. |
| ZVRA-DEBT-13794 | Warrants outstanding: 16650000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| ZVRA-DEBT-13795 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ZVRA-OWNER-WOODLINE-PARTNERS-LP | Woodline Partners LP | 90% | 13F overlay lists Woodline Partners LP as top holder; 149 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| COLL | Collegium Pharmaceutical, Inc. | 100.00 | 2 | |
| LADX | LadRx Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| SLGL | Sol-Gel Technologies Ltd. | 100.00 | 2 | |
| ABT | Abbott Laboratories | 100.00 | 2 | |
| SUPN | Supernus Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| KLRS | Kalaris Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| ELVN | Enliven Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| HLNCF | Haleon plc | 100.00 | 2 | |
| HLN | Haleon plc | 100.00 | 2 | |
| JBIO | Jade Biosciences, Inc. | 100.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| MYGN | Myriad Genetics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |